Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Androgen-Independent Prostate Cancer

NCT00121095 is registered in ClinicalTrials.gov with Cytogen Corporation as lead sponsor.

NCT NCT00121095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00121095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Androgen-Independent Prostate Cancer
Lead sponsor
Cytogen Corporation
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 31, 2005
Completion date
June 30, 2008
Enrollment
69 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms